267 related articles for article (PubMed ID: 25971465)
1. Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy.
Quinn EM; Fleming C; O'Sullivan MJ
Ir J Med Sci; 2016 May; 185(2):383-92. PubMed ID: 25971465
[TBL] [Abstract][Full Text] [Related]
2. Good adherence to adjuvant endocrine therapy in early breast cancer - a population-based study based on the Swedish Prescribed Drug Register.
Lundgren C; Lindman H; Rolander B; Ekholm M
Acta Oncol; 2018 Jul; 57(7):935-940. PubMed ID: 29493327
[TBL] [Abstract][Full Text] [Related]
3. Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross-sectional survey.
Xu H; Jin F; Zhang XJ; Wang DQ; Yu SF; Wang AP
Cancer Med; 2020 Jun; 9(11):3703-3713. PubMed ID: 32237070
[TBL] [Abstract][Full Text] [Related]
4. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
[TBL] [Abstract][Full Text] [Related]
6. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer.
Kuba S; Ishida M; Nakamura Y; Taguchi K; Ohno S
Breast Cancer; 2016 Jan; 23(1):128-133. PubMed ID: 24934610
[TBL] [Abstract][Full Text] [Related]
7. Geographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.
Tan X; Camacho F; Marshall VD; Donohoe J; Anderson RT; Balkrishnan R
Res Social Adm Pharm; 2017; 13(4):796-810. PubMed ID: 27641308
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
[TBL] [Abstract][Full Text] [Related]
9. Adherence to adjuvant endocrine therapy in women with breast cancer.
Danilak M; Chambers CR
J Oncol Pharm Pract; 2013 Jun; 19(2):105-10. PubMed ID: 22895656
[TBL] [Abstract][Full Text] [Related]
10. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study.
Wells KJ; Pan TM; Vázquez-Otero C; Ung D; Ustjanauskas AE; Muñoz D; Laronga C; Roetzheim RG; Goldenstein M; Carrizosa C; Nuhaily S; Johnson K; Norton M; Sims E; Quinn GP
Support Care Cancer; 2016 Oct; 24(10):4123-30. PubMed ID: 27146492
[TBL] [Abstract][Full Text] [Related]
11. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Breast; ; . PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
